Payment overview · 2025
General Payments
$1,304.71
48 reported records · 20 companies
Healthcare provider profile · identity verified
Mustafa Mandviwala, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · TOMBALL, TX · NPI 1982606448
Verified facts
What the public records show
CMS Open Payments records show Mustafa Mandviwala, MD received $1,304.71 in general payments during 2025 across 48 reported records.
Endologix LLC accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Endologix LLC | Unresolved — no canonical attribution shown | $217.89 | 16.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $145.40 | 11.1% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $129.38 | 9.9% | 6 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $118.62 | 9.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $90.02 | 6.9% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $79.40 | 6.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.93 | 5.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.42 | 4.5% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.56 | 4.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.78 | 3.7% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $45.50 | 3.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$45.26 | 3.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.51 | 3.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.51 | 2.3% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $26.32 | 2.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.55 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.73 | 1.7% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $21.17 | 1.6% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $16.05 | 1.2% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.71 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,304.71 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $217.89 | 3 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $217.89 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $145.40 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $129.38 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $90.02 | 4 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $85.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $59.42 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.78 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $45.50 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $45.50 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $45.26 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $33.45 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $33.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.51 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $26.32 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 119 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 39 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
88 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 109 |
| Clopidogrel | Clopidogrel Bisulfate | 296 | 96 |
| Losartan Potassium | Losartan Potassium | 295 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 282 | 85 |
| Furosemide | Furosemide | 255 | 90 |
| Eliquis | Apixaban | 217 | 50 |
| Ranolazine Er | Ranolazine | 201 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 57 |
| Repatha Sureclick | Evolocumab | 184 | 35 |
| Lisinopril | Lisinopril | 151 | 44 |
| Nifedipine Er | Nifedipine | 148 | 44 |
| Gabapentin | Gabapentin | 144 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 45 |
| Jardiance | Empagliflozin | 142 | 39 |
| Carvedilol | Carvedilol | 140 | 44 |
| Atenolol | Atenolol | 138 | 33 |
| Farxiga | Dapagliflozin Propanediol | 119 | 27 |
| Clonidine Hcl | Clonidine Hcl | 114 | 37 |
| Metformin Hcl | Metformin Hcl | 108 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 101 | 33 |
| Xarelto | Rivaroxaban | 101 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 32 |
| Entresto | Sacubitril/Valsartan | 88 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 23 |
| Metformin Hcl Er | Metformin Hcl | 61 | 22 |
| Spironolactone | Spironolactone | 54 | 19 |
| Vascepa | Icosapent Ethyl | 53 | 14 |
| Alprazolam | Alprazolam | 51 | 14 |
| Chlorthalidone | Chlorthalidone | 44 | 14 |
| Memantine Hcl | Memantine Hcl | 44 | 11 |
| Potassium Chloride | Potassium Chloride | 43 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 11 |
| Simvastatin | Simvastatin | 42 | 11 |
| Nitroglycerin | Nitroglycerin | 37 | 24 |
| Ozempic | Semaglutide | 37 | 13 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 11 |
| Irbesartan | Irbesartan | 29 | 11 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Praluent Pen | Alirocumab | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Omeprazole | Omeprazole | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,304.71 · 48 records | Endologix LLC | ARTIX MT, Assure WCD, CAPVAXIVE, CARDIOMEMS, CT THROMBECTOMY SYSTEM KIT, ENDOCROSS Device, FARXIGA, FLOWTRIEVER CATHETER, S, FUROSCIX, JARDIANCE, Kerendia, LEQVIO, LifeVest, MICRA, OPSUMIT, Ozempic, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, Torus Stent Graft System, UPTRAVI, VERQUVO, Venclose Maven Catheter, WATCHMAN FLX, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error